Back to Search

An Open-label Phase I/II Trial of Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Systemic Light-Chain Amyloidosis

  • Protocol Number: 202505078
  • Principal Investigator: Stockerl-Goldstein, Keith
  • Cancer Types: Leukemia, Myeloma, and Hematologic

Learn more about this study at: clinicaltrials.gov

For more information on this trial, contact us here:

Phone
800-600-3606
Email
[email protected]

Brief Summary

The purpose of this study is assess safety, safest dose, and effectiveness of venetoclax in combination with dexamethasone in participants with t(11;14) positive relapsed (comes back) or refractory (did not get better) light chain amyloidosis.

Protocol Interventions

Drug: Dexamethasone Oral, 20 mg, Drug: Daratumumab Injection, Drug: Bendamustine, Drug: Pomalidomide, Drug: Ixazomib